Home >  News >  Industry >  Pharma News >  Dr Reddys working on...

Dr Reddys working on Sputnik V stability data on 2 to 8 C temperature range

By - Ruchika Sharma
Published On 2021-04-15 07:18 GMT   |   Update On 2021-04-15 07:18 GMT
Advertisement

New Delhi: Dr Reddy's Laboratories is in the process of generating additional stability data for Russia's COVID-19 vaccine Sputnik V, which has a storage condition of -18C, on 2 to 8 C, a senior official of the drug maker said on Wednesday.

Deepak Sapra, Dr Reddys Chief Executive Officer, API and Services said in a press conference that the vaccine will be imported in a frozen condition from Russian Direct Investment Fund (RDIF) with which it has an agreement to distribute 125 million human doses ( 250 million vials) in India, maintaining -18 to -22.

Advertisement
The doses will be kept outside for 15-20 minutes before being administered to the people.
"In addition to the product which is at -18C, today we are in the process of generating additional stability data on the 2 to 8C temperature range.
This data will be available in a few months, after which we will make the necessary amendment request to the regulator and request for the storage condition to be modified to 2 to 8C," Sapra told reporters.
He said necessary cold storage infrastructure is in place to distribute Sputnik V vaccine in India, which will be available during the current quarter.
Dr Reddys Laboratories on Tuesday said it has received approval from Indian drug regulator for restricted emergency use of Covid-19 vaccine Sputnik in the country.
The company has received the permission from the Drug Controller General of India (DCGI) to import the Sputnik vaccine into India for restricted use in emergency situations as per the provisions of the New Drug and Clinical Trials rules, 2019 under the Drugs and Cosmetics Act, Dr Reddys had said in a regulatory filing.
In September 2020, Dr. Reddys and RDIF entered into a partnership to conduct clinical trials of the Sputnik V, developed by the Gamaleya National Research Institute of Epidemiology and Microbiology and the rights for distribution of the first 100 million doses in India.
Later it was enhanced to 125 million.
Sapre further said the quantity can be further enhanced with mutual agreement.



Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

COVID-19 Vaccine and Heart Attack: Biocon Chief, Karnataka CM get into war of words

Govt Panel Makes This Approval Mandatory For New Drug Licenses

CDSCO Panel Asks Glenmark To Justify BE Waiver for FDC Inhalation Suspension With Scientific Evidence

Sun Pharma Gets SEC Nod to Begin Phase III Trial of Cough Drug Gefapixant

USFDA grants priority review for Winrevair label update based on ZENITH Trial: Merck

AstraZeneca, Summit in discussions over USD 15 billion cancer drug licensing deal: Report

Bain Capital divests 2.4 percent stake in Emcure Pharma for Rs 563 crore

Shilpa Pharma Lifesciences Unit-1 successfully completes GMP inspection from Brazilian regulatory authority